{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=selumetinib+%28oral%29&page=2", "query": { "intervention": "selumetinib (oral)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=selumetinib+%28oral%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=selumetinib+%28oral%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T09:34:25.279Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04924608", "title": "Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurofibromatosis 1", "Plexiform Neurofibroma (PN)" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2021-11-19", "completion_date": "2029-02-15", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 4, "location_summary": "Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04924608" }, { "nct_id": "NCT00085787", "title": "A Study of ARRY-142886 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "ARRY-142886, MEK inhibitor; oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-06", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 3, "location_summary": "Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085787" }, { "nct_id": "NCT03326310", "title": "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia", "Myelofibroses" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-09-04", "completion_date": "2027-09-04", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326310" }, { "nct_id": "NCT02768766", "title": "Intermittent Selumetinib for Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Selumetinib, 100mg", "type": "DRUG" }, { "name": "Selumetinib, 125mg", "type": "DRUG" }, { "name": "Selumetinib, 150mg", "type": "DRUG" }, { "name": "Selumetinib, 175mg", "type": "DRUG" }, { "name": "Selumetinib, 200mg", "type": "DRUG" }, { "name": "Selumetinib, 225mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shaheer A. Khan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2017-02-28", "completion_date": "2020-09-18", "has_results": false, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02768766" }, { "nct_id": "NCT01313039", "title": "Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AZ6244", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2011-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313039" }, { "nct_id": "NCT01750281", "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib 75 mg", "type": "DRUG" }, { "name": "Docetaxel 75 mg/m2", "type": "DRUG" }, { "name": "Docetaxel 60 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2012-12-18", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750281" }, { "nct_id": "NCT02056392", "title": "To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "selumetinib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 54, "start_date": "2014-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-09", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02056392" }, { "nct_id": "NCT00600496", "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Neoplasms", "Colon Cancer", "Colonic Cancer", "Colon Neoplasms", "Lung Cancer", "Melanoma", "Kidney Cancer" ], "interventions": [ { "name": "AZD6244", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 140, "start_date": "2007-12-14", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 4, "location_summary": "Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600496" }, { "nct_id": "NCT02063204", "title": "To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2014-03", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-06-30", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02063204" }, { "nct_id": "NCT01217450", "title": "Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-10", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-29", "last_synced_at": "2026-10-09T09:34:25.279Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217450" } ] }